Markets
FBL-WC-CLUB-2025-MATCH63-CHELSEA-PSG
US President Donald Trump at the FIFA Club World Cup Final (Franck Fife/Getty Images)

US stock futures slump as Trump announces tariff hikes on the European Union, Mexico

We’re nearing a “make-it-or-break-it moment” on tariffs, warns ING Economics.

Luke Kawa
7/13/25 5:29PM

There’s no time off from tariff announcements, with S&P 500 futures trading 0.5% lower on Sunday evening in response to the threat of higher levies on imports from two of America’s biggest trading partners.

After the close on Friday, President Donald Trump posted a pair of letters to Truth Social announcing 30% tariffs on imports from Mexico and European Union, separate from any sectoral tariffs, effective August 1.

For the EU, Trump cited the US’s longstanding trade deficit with the bloc; in the case of Mexico, he said the same while adding that the nation has not done enough to help secure the border. The euro and Mexican peso are also weakening versus the US dollar in early trading.

The market’s reaction to the flurry of tariff news in 2025 has looked a little something like this:

  • Trump floats a ton of onerous tariffs;

  • Trump delays and/or waters down these tariffs;

  • Tariff rates, in aggregate, still go up materially; and

  • Stock markets (and earnings estimates) keep going up, in part because initial announcements of onerous tariffs are yet to be fully realized.

The narrative increasingly embedded in the markets is that tariffs are here, but won’t be as bad as once feared or enough to tip the US economy into a recession.

Strategists are divided on whether these latest declarations make deals before the new August 1 deadline more or less likely.

“August 1 is less than three weeks away, and as it seems unlikely that the Trump Administration can offer one ally something it does not offer all (e.g. say a special deal on autos for say Japan, but not South Korea or the EU), the prospects for a negotiated outcome and avoiding broad based trade escalation by the end of the month has now fallen even lower,” wrote Jacob Funk Kirkegaard of 22V Research.

On the other hand...

“On the EU side, the 30% threat will resonate, and — we think — act as a catalyst to force the EU to accept a deal that it may not have countenanced before (e.g. with only limited US concessions regarding autos),” Nico FitzRoy, senior Europe strategist at Signum Global Research, wrote. “On the US side, we think the most likely reasoning behind’s Trump’s announcement is to use the 30% threat to squeeze out as good a deal as possible from the EU (rather than simply wanting to implement the tariff), as we believe recent events suggest there is now enough evidence Trump actually wants a deal.”

And others, reasonably, are happy to say that they aren’t sure.

“We have given up speculating about any longer-term strategies in these trade negotiations,” ING Economics’ Carsten Brzeski and Inga Fechner wrote. “What the letters of the last days, and in particular the letters to the EU and Mexico, show is that we are nearing a make-it-or-break-it moment.”

More Markets

See all Markets
markets

Jeep maker Stellantis surges as CEO says the automaker is in productive tariff talks with the US

Shares of Jeep and Dodge maker Stellantis are up more than 8% in Thursday afternoon trading, following comments from the automaker’s new CEO, Antonio Filosa, at a European auto conference.

On tariffs, Filosa said that Stellantis has had a “very productive exchange of ideas” with the Trump administration on the company’s manufacturing footprint and that the environment around the levies is “getting clearer and clearer.”

The US is Stellantis’ top priority, according to Filosa, and the company has taken efforts to turn things around in the market, where its struggled with sales in recent years. To fuel the turnaround, Stellantis is bringing back its popular Jeep Cherokee, which it discontinued in 2023.

As of 12:45 p.m. ET, Stellantis’ trading volume was at more than 140% of its average over the past 30 days.

markets

Tempus AI jumps on FDA clearance of AI-enabled tool to analyze cardiac MRIs

Tempus AI, a midcap medical diagnostics company that’s highlighted a push to incorporate AI technology into its products, surged on Thursday after announcing the FDA had issued a “510(k) clearance” of a new AI-enabled tool to analyze cardiac imagery from MRIs.

A 510(k) clearance — used for devices that are considered relatively low risk — essentially allows a product to be sold in the US.

While the company has never turned a profit, even on an adjusted basis, its sales are growing rapidly and the stock has had a great year, rising more than 160% in 2025.

For more on the company, check out our interview with its CEO, Eric Lefkofsky.

While the company has never turned a profit, even on an adjusted basis, its sales are growing rapidly and the stock has had a great year, rising more than 160% in 2025.

For more on the company, check out our interview with its CEO, Eric Lefkofsky.

markets

Micron surges as Citi boosts price target to $175

Micron is on the move this morning, gapping higher and continuing to trade up double digits after Citi boosted its view on how much the shares can run.

Analyst Christopher Danely raised his price target on the memory chipmaking specialist to $175 from $150, while maintaining a “buy” rating. The average analyst price target of $151 has now been shattered by Micron’s rise today, and the stock is trading at its highest level since June 2024.

This continues Micron’s advance as OpenAI’s dogged determination to burn through cash to enhance its AI capabilities provides a broad lift to the space, punctuated by Oracle’s massive gain on Wednesday.

Call demand is running hot: just 13 minutes into the session, volumes are running at 106,157 compared to a 20-day average of 88,888.

Micron is slated to report quarterly results on September 23.

markets

Centene rises after affirming full-year guidance

Centene soared in early trading after affirming its full-year guidance ahead of the Deutsche Bank 2025 Healthcare Summit on Thursday.

The company reiterated its expectation for adjusted diluted earnings per share to be approximately $1.75. At the conference, Centene executives also said they expect a higher percentage of its Medicare enrollees to be on more lucrative, top-rated plans next year, according to Bloomberg.

Earlier this week, UnitedHealth also reiterated its guidance and said it expects to have more top-rated plans in the coming year. The government rates insurance companies offering Medicare Advantage plans, and higher-rated plans are eligible for bonuses that can significantly increase a plan’s revenue.

Insurance companies that sell government-sponsored plans took a dive earlier this year amid unexpected rising costs. The recent announcements from both Centene and UnitedHealth may be a sign that the worst is behind them.

markets

Delta boosts its third-quarter sales outlook on improved travel demand

Delta Air Lines reaffirmed its full-year earnings outlook on Thursday, seeing US travel demand hold strong for the rest of the year.

Citing “improved demand trends,” the airline also elevated its sales forecast for the third quarter to an increase of between 2% and 4%. In July, it guided for 0% to 4% growth.

The move marks a turnaround from just five months ago, when Delta and many of its rivals pulled their full-year earnings outlooks as growth stalled on “broad economic uncertainty.” At the beginning of the year, Delta said 2025 had the chance to be its best fiscal year in a century.

After plunging earlier this year, Delta’s shares are essentially flat in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.